Conexeu Sciences Inc.

CNXU

NASDAQHealthcareBiotechnology

在 GoAI 中打開

前收盤價

US$8.89

−US$0.54 · -5.73%

8月21日下午4:00 ET

歷史價格可能經過調整並有所延遲。

公司概況

Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell, and operates from its primary office in Reno, Nevada.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Miles Harrison
上市以來: 2026年5月21日
僱員: 4

市場位置

日內區間

目前US$8.89，

US$8.68US$10.2909

52週區間

目前US$8.89，

US$6.85US$18.79

開盤價: US$9.42
前收盤價: US$9.43
成交量: 40.37萬; 2.97× 平均值
平均成交量: 13.6萬; 日均成交量
市值: 2.38億 USD
貝塔: 0.51; 市場參考 1
50天平均值: US$9.7068; 低於平均水平-8.41%
200天平均值: US$10.70; 低於平均水平-16.92%

分析師評級

第三方分析師預期可能變動，並非 GoAI 建議。

分析師目標價

平均目標

US$20.00

上漲空間 124.97%

過去 12 個月12個月預測最高：US$20.00平均的：US$20.00最低：US$20.00

CNXU 訊息

globenewswire.com2026年8月18日

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu's CXU™ Platform

閱讀原始碼

prnewswire.com2026年7月15日

The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.

/PRNewswire/ -- Equity Insider News Commentary - Every so often, a wave of demand in one corner of medicine spills over and creates an entirely new market next

閱讀原始碼

globenewswire.com2026年7月14日

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It

Highlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed.

閱讀原始碼

globenewswire.com2026年7月7日

A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill

Study Highlights P.R.O.O.F study complete, marking an important catalyst. Conexeu has completed its P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical program, which provides the evidence…

閱讀原始碼

globenewswire.com2026年6月25日

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre

閱讀原始碼

seekingalpha.com2026年6月24日

Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission

Conexeu Sciences is rated Buy, leveraging a patented CXU platform targeting multi-billion-dollar regenerative medicine markets with a flagship wound care product. CNXU's Ten-Minute Tissue™ aims for FDA 510(k) clearance…

閱讀原始碼